A number that can be moved
Educational use only. Not clinically reviewed47-year-old man for urgent recognition, immediate escalation, evidence-boundary review, and handoff practice. About 8 simulated minutes.
What you will practise
- Record the clinical picture rather than the count alone.
- Record what the count licenses and what it does not.
- Call haematology immediately, without waiting for confirmation.
- Refuse an intervention that lowers the number as proof of benefit.
- Record bounded qualified-team cytoreduction intent.
- Review the boundaries and their certainty in both directions.
- Hand off the findings that make it an emergency.
Review and sources
Not clinically reviewed. No clinician has signed this scenario.
- Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia — a systematic review and meta-analysis. Transfusion. 2020;60(10):2360-2369. Up to 20% of patients with acute myeloid leukemia present with hyperleukocytosis, usually defined as a white blood cell count greater than 100 x 10^9/L; given the high early mortality rate, emergent cytoreduction is indicated but the optimal strategy is unknown. Across 13 two-arm retrospective studies with 1743 patients (486 leukapheresis, 1257 not), leukapheresis did not improve early mortality (risk ratio 0.88, 95% CI 0.69-1.13, P=.321). Patients presenting with clinical leukostasis tended to be more likely to undergo leukapheresis (odds ratio 2.01, 95% CI 0.99-4.08, P=.052). The authors argue against routine use.
- Duminuco A, Del Fabro V, De Luca P, Leotta D. Emergencies in Hematology: Why, When and How I Treat? J Clin Med. 2024;13(24):7572. A narrative review. Clinical choices in hyperleukocytosis are crucial within the first hours, and a recent systematic review found no evidence of standardised guidelines for managing it. Pulmonary and neurological signs are the manifestations most strongly linked to early mortality.
Open Sim Lab is an educational simulator, not for clinical use. It is not a clinical decision-support tool, not a dosing calculator, and is not validated for any decision affecting a real patient.